Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Eastern Canadian Colorectal Cancer Consensus Conference 2017.

McGee SF, AlGhareeb W, Ahmad CH, Armstrong D, Babak S, Berry S, Biagi J, Booth C, Bossé D, Champion P, Colwell B, Finn N, Goel R, Gray S, Green J, Harb M, Hyde A, Jeyakumar A, Jonker D, Kanagaratnam S, Kavan P, MacMillan A, Muinuddin A, Patil N, Porter G, Powell E, Ramjeesingh R, Raza M, Rorke S, Seal M, Servidio-Italiano F, Siddiqui J, Simms J, Smithson L, Snow S, St-Hilaire E, Stuckless T, Tate A, Tehfe M, Thirlwell M, Tsvetkova E, Valdes M, Vickers M, Virik K, Welch S, Marginean C, Asmis T.

Curr Oncol. 2018 Aug;25(4):262-274. doi: 10.3747/co.25.4083. Epub 2018 Aug 14.

2.

LBA-003Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

Bendell J, Hubbard J, O'Neil BH, Jonker D, Starodub A, Peyton J, Pitot H, Halfdanarson T, Nadeau B, Zubkus J, Adesunloye B, Edenfield J, Li YZ, Li W, Grothey A, Borodyansky L, Li CJ.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.002. No abstract available.

PMID:
30052785
3.

Predictors of consent to cell line creation and immortalisation in a South African schizophrenia genomics study.

Campbell MM, de Vries J, Mqulwana SG, Mndini MM, Ntola OA, Jonker D, Malan M, Pretorius A, Zingela Z, Van Wyk S, Stein DJ, Susser E.

BMC Med Ethics. 2018 Jul 11;19(1):72. doi: 10.1186/s12910-018-0313-2.

4.

Piloting a mental health training programme for community health workers in South Africa: an exploration of changes in knowledge, confidence and attitudes.

Sibeko G, Milligan PD, Roelofse M, Molefe L, Jonker D, Ipser J, Lund C, Stein DJ.

BMC Psychiatry. 2018 Jun 14;18(1):191. doi: 10.1186/s12888-018-1772-1.

5.

Health related quality of life in older or frail patients with advanced colorectal cancer treated with dose reduced capecitabine.

Breadner D, Vincent MD, Jonker D, Cripps C, Klimo P, Biagi J, Lam W, O'Connell A, Whiston F, Stitt L, Welch S.

J Geriatr Oncol. 2018 May 1. pii: S1879-4068(18)30140-1. doi: 10.1016/j.jgo.2018.04.002. [Epub ahead of print]

PMID:
29728308
6.

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.

De Mattia E, Cecchin E, Montico M, Labriet A, Guillemette C, Dreussi E, Roncato R, Bignucolo A, Buonadonna A, D'Andrea M, Coppola L, Lonardi S, Lévesque E, Jonker D, Couture F, Toffoli G.

Front Pharmacol. 2018 Apr 13;9:367. doi: 10.3389/fphar.2018.00367. eCollection 2018.

7.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Mar 8. pii: S1533-0028(17)30462-0. doi: 10.1016/j.clcc.2018.03.001. [Epub ahead of print]

PMID:
29653857
8.

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ.

Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1.

PMID:
29397354
9.

A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer.

Maroun J, Marginean H, Jonker D, Cripps C, Goel R, Asmis T, Goodwin R, Chiritescu G.

Clin Colorectal Cancer. 2018 Jun;17(2):e257-e268. doi: 10.1016/j.clcc.2017.12.003. Epub 2017 Dec 15.

10.

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.

Grigor EJM, Fergusson DA, Haggar F, Kekre N, Atkins H, Shorr R, Holt RA, Hutton B, Ramsay T, Seftel M, Jonker D, Daugaard M, Thavorn K, Presseau J, Lalu MM.

BMJ Open. 2017 Dec 29;7(12):e019321. doi: 10.1136/bmjopen-2017-019321.

11.

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L.

Labriet A, De Mattia E, Cecchin E, Lévesque É, Jonker D, Couture F, Buonadonna A, D'Andrea M, Villeneuve L, Toffoli G, Guillemette C.

Front Pharmacol. 2017 Oct 10;8:712. doi: 10.3389/fphar.2017.00712. eCollection 2017.

12.

PET imaging in anal canal cancer: a systematic review and meta-analysis.

Mahmud A, Poon R, Jonker D.

Br J Radiol. 2017 Dec;90(1080):20170370. doi: 10.1259/bjr.20170370. Epub 2017 Oct 3. Review.

PMID:
28972796
13.

Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer.

Vincent MD, Breadner D, Cripps MC, Jonker DJ, Klimo P, Biagi JJ, Lam W, O'Connell A, Whiston F, Stitt L, Welch SA.

Curr Oncol. 2017 Aug;24(4):e261-e268. doi: 10.3747/co.24.3516. Epub 2017 Aug 31.

14.

Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review.

Gotfrit J, Vickers M, Sud S, Asmis T, Cripps C, Goel R, Hsu T, Jonker D, Goodwin R.

Curr Oncol. 2017 Aug;24(4):234-239. doi: 10.3747/co.24.3562. Epub 2017 Aug 31.

15.

Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: A Cancer Care Ontario Systematic Review.

Meyers BM, Cosby R, Quereshy F, Jonker D.

Clin Oncol (R Coll Radiol). 2017 Jul;29(7):459-465. doi: 10.1016/j.clon.2017.03.001. Epub 2017 Mar 22. Review.

PMID:
28341242
16.

Structured Multidisciplinary work Evaluation Tool: Development and validation of a multidisciplinary work questionnaire.

Haraldsson P, Jonker D, Strengbom E, Areskoug-Josefsson K.

Work. 2016;55(4):883-891. doi: 10.3233/WOR-162454.

PMID:
28059819
17.

Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline.

Meyers BM, Cosby R, Quereshy F, Jonker D.

Curr Oncol. 2016 Dec;23(6):418-424. doi: 10.3747/co.23.3330. Epub 2016 Dec 21.

18.

Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.

Morgen EK, Lenz HJ, Jonker DJ, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis CS, Dobrovic A, O'Callaghan CJ, Liu G.

Pharmacogenomics J. 2017 Dec;17(6):535-542. doi: 10.1038/tpj.2016.56. Epub 2016 Nov 29. Review.

PMID:
27897268
19.

Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.

Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D.

Pancreatology. 2016 Nov - Dec;16(6):1106-1112. doi: 10.1016/j.pan.2016.08.013. Epub 2016 Aug 30.

PMID:
27600995
20.

Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid.

Yan M, Ho C, Winquist E, Jonker D, Rayson D, Stitt L, Tokmakejian S, Tomiak A, Vincent MD.

Clin Colorectal Cancer. 2016 Dec;15(4):369-376.e3. doi: 10.1016/j.clcc.2016.06.001. Epub 2016 Jun 23.

PMID:
27474080
21.

Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial.

Courneya KS, Vardy JL, O'Callaghan CJ, Friedenreich CM, Campbell KL, Prapavessis H, Crawford JJ, O'Brien P, Dhillon HM, Jonker DJ, Chua NS, Lupichuk S, Sanatani MS, Gill S, Meyer RM, Begbie S, Bonaventura T, Burge ME, Turner J, Tu D, Booth CM.

Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):969-77. doi: 10.1158/1055-9965.EPI-15-1267. Epub 2016 Apr 8.

22.

Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.

Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A.

Clin Cancer Res. 2016 May 15;22(10):2435-44. doi: 10.1158/1078-0432.CCR-15-0414.

23.

A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.

Chen EX, Jonker DJ, Siu LL, McKeever K, Keller D, Wells J, Hagerman L, Seymour L.

Invest New Drugs. 2016 Aug;34(4):450-7. doi: 10.1007/s10637-016-0351-x. Epub 2016 Apr 13.

PMID:
27075016
24.

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies.

Goss GD, Jonker DJ, Laurie SA, Weberpals JI, Oza AM, Spaans JN, la Porte C, Dimitroulakos J.

J Transl Med. 2016 Mar 31;14:83. doi: 10.1186/s12967-016-0836-6.

25.

Tissue Factor Pathway Inhibitor Gene Polymorphism -33T → C Predicts Improved Disease-Free Survival in Colorectal Cancer.

Bazzarelli AK, Scheer AS, Tai LH, Seth R, de Souza CT, Petrcich W, Jonker DJ, Maroun JA, Carrier M, Auer RC.

Ann Surg Oncol. 2016 Jul;23(7):2274-80. doi: 10.1245/s10434-016-5169-4. Epub 2016 Mar 11.

PMID:
26968713
26.

Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.

Di Valentin T, Asmis T, Asselah J, Aubin F, Aucoin N, Berry S, Biagi J, Booth CM, Burkes R, Coburn N, Colwell B, Cripps C, Dawson LA, Dorreen M, Frechette D, Goel R, Gray S, Hammad N, Jonker D, Kavan P, Maroun J, Nanji S, Roberge D, Samson B, Seal M, Shabana W, Simunovic M, Snow S, Tehfe M, Thirlwell M, Tsvetkova E, Vickers M, Vuong T, Goodwin R.

Curr Oncol. 2016 Feb;23(1):52-5. doi: 10.3747/co.23.2897. Epub 2016 Feb 18.

27.

Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.

Horgan AM, Darling G, Wong R, Guindi M, Liu G, Jonker DJ, Lister J, Xu W, MacKay HM, Dinniwell R, Kim J, Pierre A, Shargall Y, Asmis TR, Agboola O, Seely AJ, Ringash J, Wells J, Marginean EC, Haider M, Knox JJ.

Dis Esophagus. 2016 Nov;29(8):1152-1158. doi: 10.1111/dote.12444. Epub 2015 Dec 10.

PMID:
26663741
28.

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.

Lheureux S, Oza AM, Laurie SA, Halford R, Jonker D, Chen E, Keller D, Bourade V, Wang L, Doyle L, Siu LL, Goel R.

Br J Cancer. 2015 Dec 1;113(11):1534-40. doi: 10.1038/bjc.2015.343. Epub 2015 Nov 10.

29.

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.

Meulendijks D, Lassen UN, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD, Schellens JH.

Clin Cancer Res. 2016 Feb 15;22(4):858-67. doi: 10.1158/1078-0432.CCR-15-1506. Epub 2015 Oct 7.

30.

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.

Chen S, Villeneuve L, Jonker D, Couture F, Laverdière I, Cecchin E, Innocenti F, Toffoli G, Lévesque E, Guillemette C.

Pharmacogenet Genomics. 2015 Dec;25(12):573-83. doi: 10.1097/FPC.0000000000000168.

PMID:
26352872
31.

Caregiver-mediated therapy for an adult with visual and intellectual impairment suffering from separation anxiety.

Jonker D, Sterkenburg PS, Van Rensburg E.

Res Dev Disabil. 2015 Dec;47:1-13. doi: 10.1016/j.ridd.2015.08.005. Epub 2015 Aug 28.

PMID:
26321690
32.

The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas.

Paliga A, Marginean H, Tessier-Cloutier B, Purgina B, Jonker D, Marginean EC.

Am J Clin Oncol. 2017 Dec;40(6):543-551. doi: 10.1097/COC.0000000000000202.

PMID:
26125303
33.

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA.

Eur J Cancer. 2015 Jul;51(11):1405-14. doi: 10.1016/j.ejca.2015.03.015. Epub 2015 May 12.

PMID:
25979833
34.

Rapid and reliable discrimination between Shigella species and Escherichia coli using MALDI-TOF mass spectrometry.

Paauw A, Jonker D, Roeselers G, Heng JM, Mars-Groenendijk RH, Trip H, Molhoek EM, Jansen HJ, van der Plas J, de Jong AL, Majchrzykiewicz-Koehorst JA, Speksnijder AG.

Int J Med Microbiol. 2015 Jun-Aug;305(4-5):446-52. doi: 10.1016/j.ijmm.2015.04.001. Epub 2015 Apr 13.

PMID:
25912807
35.

A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients.

Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E, Villeneuve L, Harvey M, Court MH, Innocenti F, Toffoli G, Lévesque E, Guillemette C.

Pharmacogenomics J. 2015 Dec;15(6):513-20. doi: 10.1038/tpj.2015.12. Epub 2015 Mar 17.

PMID:
25778466
36.

Review of anal cancer patients at the Ottawa hospital.

Abunassar M, Reinders J, Jonker DJ, Asmis T.

Eur J Surg Oncol. 2015 May;41(5):653-8. doi: 10.1016/j.ejso.2015.02.004. Epub 2015 Mar 4.

PMID:
25776438
37.

Health surveillance under adverse ergonomics conditions--validity of a screening method adapted for the occupational health service.

Jonker D, Gustafsson E, Rolander B, Arvidsson I, Nordander C.

Ergonomics. 2015;58(9):1519-28. doi: 10.1080/00140139.2015.1019575. Epub 2015 Mar 12.

38.

A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.

Lassen UN, Meulendijks D, Siu LL, Karanikas V, Mau-Sorensen M, Schellens JH, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD.

Clin Cancer Res. 2015 Jan 15;21(2):258-66. doi: 10.1158/1078-0432.CCR-14-1334. Epub 2014 Nov 11.

39.

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.

Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L.

Invest New Drugs. 2015 Apr;33(2):321-31. doi: 10.1007/s10637-014-0171-9. Epub 2014 Nov 8.

PMID:
25380635
40.

Use of chemotherapy and radiofrequency ablation to treat colorectal cancer metastases: a retrospective review of The Ottawa Hospital Cancer Centre over 7 years.

Boame N, Gresham G, Jonker D, Martel G, Balaa F, Asmis T.

Curr Oncol. 2014 Aug;21(4):e557-63. doi: 10.3747/co.21.1929.

41.

Role of fine-needle aspiration in the surgical management of pancreatic neuroendocrine tumors: utility and limitations in light of the new World Health Organization classification.

Moyana TN, Kendal WS, Chatterjee A, Jonker DJ, Maroun JA, Grimard L, Shabana W, Mimeault R, Hakim SW.

Arch Pathol Lab Med. 2014 Jul;138(7):896-902. doi: 10.5858/arpa.2013-0300-OA.

PMID:
24978915
42.

Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.

Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ.

BMC Cancer. 2014 Jun 27;14:471. doi: 10.1186/1471-2407-14-471. Review.

43.

Patterns of recurrence following selective intraoperative radiofrequency ablation as an adjunct to hepatic resection for colorectal liver metastases.

Eltawil KM, Boame N, Mimeault R, Shabana W, Balaa FK, Jonker DJ, Asmis TR, Martel G.

J Surg Oncol. 2014 Nov;110(6):734-8. doi: 10.1002/jso.23689. Epub 2014 Jun 25.

PMID:
24965163
44.

Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review.

Spithoff K, Cummings B, Jonker D, Biagi JJ; Gastrointestinal Cancer Disease Site Group.

Clin Oncol (R Coll Radiol). 2014 Aug;26(8):473-87. doi: 10.1016/j.clon.2014.03.005. Epub 2014 Apr 8. Review.

PMID:
24721444
45.

The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17.

Sommeijer DW, Karapetis CS, Zalcberg JR, Tu D, Jonker DJ, Simes J, Tebbutt N, Yip D, Price TJ, O'Callaghan CJ.

Acta Oncol. 2014 Jul;53(7):877-84. doi: 10.3109/0284186X.2013.879202. Epub 2014 Feb 5.

PMID:
24495042
46.

Thymic epithelial neoplasms: a 12-year Canadian regional cancer program experience.

Wheatley-Price P, Jonker H, Jonker D, Shamji F, Gomes MM.

Clin Lung Cancer. 2014 May;15(3):231-6. doi: 10.1016/j.cllc.2013.12.003. Epub 2013 Dec 27.

PMID:
24485232
47.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.

Jonker DJ, Karapetis CS, Harbison C, O'Callaghan CJ, Tu D, Simes RJ, Malone DP, Langer C, Tebbutt N, Price TJ, Shapiro J, Siu LL, Wong RP, Bjarnason G, Moore MJ, Zalcberg JR, Khambata-Ford S.

Br J Cancer. 2014 Feb 4;110(3):648-55. doi: 10.1038/bjc.2013.753. Epub 2013 Dec 12.

48.

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group.

Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11.

49.

Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.

Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ; NCIC Clinical Trials Group; Australasian Gastrointestinal Trials Group.

Cancer. 2014 Jan 15;120(2):181-9. doi: 10.1002/cncr.28410. Epub 2013 Oct 11.

50.

NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.

Dent SF, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, Chen EX, Lyons JF, Seymour L.

Invest New Drugs. 2013 Dec;31(6):1522-9. doi: 10.1007/s10637-013-0018-9. Epub 2013 Sep 27.

PMID:
24072436

Supplemental Content

Loading ...
Support Center